Abstract. The incidence and associated mortality of melanoma continues to increase worldwide. At present, there is no curative therapy for advanced stage of melanoma. It is necessary to find new indicators of prognosis and therapeutic targets. Increasing evidence shows that miRNA can provide potential candidate biomarkers for melanoma and therapeutic targets. GEF-H1, a regulator of RhoA, as oncogenic driver in melanoma, promotes the growth and invasion of melanoma. miR-194 is a tumor-suppressor gene in multiple tumors, such as bladder and non-small cell lung cancer, and clear cell renal cell carcinoma. In the present study, we demonstrated that GEF-H1 serves as target of miR-194. Overexpression of miR-194 downregulates the GEF-H1/RhoA pathway, inhibits melanoma cancer cell proliferation and metastasis. Furthermore, miR-194 expression is negatively associated with tumor-node-metastasis (TNM) stages. Briefly, our findings provided new theoretical basis for melanoma treatment.
Introduction
Melanoma is a common malignant tumor, and the most aggressive form of skin cancer, which incidence keeps increasing worldwide (1) . Despite expectations that targeted therapies based on mutations intended to improve the survival of patients, current regiments are not satisfactory (2) . New therapies, including mitogen-activated protein kinase (3) pathway inhibitors, such as BRAF and MEK inhibitors, as well as other signaling pathways inhibitors, are being tested in metastatic melanoma either as immunotherapy or in combination, and have yielded promising results (4) . However, we still need to find novel targets for treatment of melanoma.
Rho guanine nucleotide exchange factor (5) is a protein which regulates the activity of Rho GTP enzyme through regulating the exchange of GDP/GTP (6) . GEF-H1 has a wide range of biological functions, such as regulating vesicle transport and cell movement (6, 7) , stabling cytoskeleton (8) , affecting the cell barrier function (9) (10) (11) (12) , promoting cell cycle progression and inhibiting cell apoptosis and other biological functions (5, 10, (12) (13) (14) (15) . GEF-H1 has been reported to have abnormal activation in many types of cancers, such as breast, prostate and myeloid cell cancer (10, (16) (17) (18) (19) (20) . There are also several studies showing that GEF-H1 was overexpressed in brain metastatic melanoma (12) . GEF-H1 induces the activation of RhoA oncogene (21) (22) (23) , and then activates various signals pathways, such as proliferation, metastasis and cytoskeleton reorganization (24) .
MicroRNA (miRNA) is an endogenous short chain RNA with a length of ~22 nt. Through endogenous RNA interference machinery they can repress multiple target genes (25) (26) (27) . In a variety of cancers, the prognosis of patients was considered to be close to the expression of miRNAs. Increasing reports show that miRNAs played important roles in cell differentiation, individual development, cell growth and metastasis (28) . Muller and Bosserhoff found that several of the miR-let-7 family members had decreased expression in melanoma and miR-let-7a reduced NRAS expression in melanoma (29) . In melanoma miR-193b has been reported to be downregulated with overexpression of cyclin D1; then, promoting the proliferative capacity of melanoma (30) . Also it was demonstrated that cancer growth was reduced when miR-205 was overexpressed (31, 32) . All these studies indicated that miRNA regulates multiple targets then affect the biological functions of melanoma cells.
miR-194 has been reported to suppress invasion and migration of liver cancer cells (33) . Experiments showed that miR-194 has a low expression in colon cancer (34) . Previous research showed that miR-194 expression was associated with the advanced stage in gastric cancer (35) . However, there is no previous study concerning the expression and function of miR-194 in melanoma.
In the present study, we studied the expression of miR-194 and GEF-H1 in melanoma using real-time PCR, and investigated the association between miR-194 and GEF-H1. Results showed that miR-194 had a negative correlation with the tumor-node-metastasis (TNM) stage of melanoma, and it suppresses the growth and metastasis of melanoma cells by downregulating the expression of GEF-H1. Table II .
Materials and methods

Tissue
Laser capture microdissection was performed on melanoma tumors that were selected when tumor blocks were readily available for the tissue sectioning required for laser capture microdissection (36) .
A375 was purchased from the American Type Culture Collection (ATCC; CRL-1619; Manassas, vA, uSA) and A875 was purchased from Shanghai Maisha Biotech. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) at 37˚C under 5% CO 2 .
MTT assays. Cells were seeded at a density of 1x10 3 cells/well of 96-well plates, and transfected with miR-194 mimic (AuGG uGuuAuCAAGuGuAACAGCAACuCCAuGuGGACuG uGuACCAAuuuCCAGuGGAGAuGCuGuuACuuuuG AuGGuuACCAA), miR-194 inhibitor (uCCACAuGGAGuu GCuGuuACA) or negative control (uCACAACCuCCuAGA AAGAGuAGA); 12 h later, the cell proliferation was evaluated by MTT assay. Microplate reader (Bio-Rad, Hercules, CA, uSA) was used to measure the optical densities at 490 nm.
Transwell assay. The Matrigel invasion chamber was used to assess cell invasion ability (24-well plates, 8-µm pore size; Corning, Corning, NY, uSA). In brief, 1x10 5 cells in serumfree media were seeded in Transwell chambers with Matrigel membranes covered or uncovered with the media containing 0.1% bovine serum albumin, while the media containing 30% FBS was placed in the lower well. Twenty-four hours after transfection with miR-194 mimic, miR-194 inhibitor or negative control cells, the non-invading cells were removed with cotton swabs. Cells at the bottom of the membrane were stained with 0.1% crystal violet and were counted by microscopy.
Quantitative real-time PCR. Total RNA from tissue samples and cells was extracted by TRIzol (Invitrogen, Carlsbad, CA, uSA) through the protocol. Real-time PCR was carried out using Real-time PCR universal reagent and the MX3000P real-time PCR instrument following the protocols. The expression of miR-194 was detected by stem-loop RT-PCR assay as previously reported (37, 38) . The primers are shown in Table I . All the reactions were carried out as previously described (39) .
Western blot analyses. The cells and tissues were lysed in lysis buffer (25 mM Tris, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA), supplemented with proteinase and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, uSA). The cell lysates were fractionated by 10% SDS-PAGE, and were transferred to a polyvinylidene difluoride membrane (Millipore Corporation, Billerica, MA, uSA). Target proteins were probed with specific antibodies: GEF-H1 (sc-134827), RhoA (sc-119), p21 (sc-21532), Ecad (sc-21791), vim (sc-80975) and GAPDH (sc-365062) (Santa Cruz Biotechnology, Santa Cruz, CA, uSA).
Dual-luciferase reporter assay. Dual-luciferase activity assays were performed as previously described (40) . The GEF-H1 3'-untranslated region (3'-UTR) was PCR amplified and cloned into the pMIR-REPORT™ vector (Ambion, Carlsbad, CA, uSA). The primers used were: GEF-H1-WT F, 5'-CCCGTC CGATTATGTCTCGG-3' and R, 5'-GCTGTCGGAGGGGT AG-3'; GEF-H1-DEL F, 5'-CCCGTCCGATTATGTCTCGG-3' and R, 5'-CGCCCCCTCACATGGTGC-3'. A375 cells were seeded into 24-well plates and co-transfected with 500 ng WT or DEL reporter vector and 10 ng pMIR-REPORT™-βgal control plasmid in miR-194 mimic and miR-194 AS. Luciferase activity was determined using the dual-luciferase reporter assay system after 36 h transfection; the luciferase activity was measured using the Dual-luciferase Reporter Assay System (Promega, Madison, WI, uSA). Immunofluorescence staining. All the reactions were carried out as previously described (41) . Briefly, ~4-µm thick slices were cut from paraffin-embedded specimens, and IHC staining was performed on tissue slices. These sections were treated at 80˚C for 30 min, deparaffinized with xylene and rehydrated after washing with different alcohol concentrations. All dewaxed slices were immersed in 0.01 mmol/l citrate buffer (pH 6.0) and maintained in high-pressure steam at 121˚C for 4 min to fix antigenicity. Afterwards, the slices were cooled to room temperature. To remove the endogenous peroxidase activity, the slices were placed in 3% hydrogen peroxide for 10 min. Tissue sections were incubated with GEF-H1 antibody (sc-134827) (1:200) at 4˚C overnight, washed three times (5 min each) with phosphate-buffered saline, and finally incubated with biotin-labeled secondary antibody and horseradish peroxidase-conjugated streptavidin for 20 min. All slices were immersed in 3,3'-diamino-benzidine tetrahydrochloride (Dako Corporation, Glostrup, Denmark) at 37˚C, which was followed by hematoxylin counterstaining.
Statistical analysis. In the present study χ 2 test was used to analyze the relationship between miR-194 and clinicopathological variables. A univariate analysis of log-rank test was used to evaluate the differences among the levels of possible prognostic factors. All the data were analyzed with SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Statistical significance was defined as p<0.05. All experiments were repeated three times.
Results
Expression of GEF-H1 in melanoma tissues. In order to study the relationship between GEF-H1 and melanoma, we detected the expression of GEF-H1 in tumor and adjacent tissues by real-time PCR, western blotting and immunofluorescence staining (Fig. 1A, B and E) . The adjacent tissues were used as a control. Results showed that there was a higher expression of GEF-H1 in melanoma tissues than the adjacent tissues. Furthermore, in order to explore the relationship between GEF-H1 and melanoma, we selected melanoma tissues of different TNM stages to test the expression of GEF-H1 by real-time PCR, western blotting and immunofluorescence staining (Fig. 1C, D and F) . We found that with the increase of TNM grade of melanoma, the expression of GEF-H1 was increased.
miR-194 inhibits the expression of GEF-H1 in A375 cells.
miR-194 has been reported downregulated in various types of cancers (42) , however, its expression in melanoma has not been reported. To test the expression of miR-194 in tumor and adjacent tissues, we used real-time PCR assay ( Fig. 2A) . We found that the expression of 194 in tumor tissues was lower than that in the adjacent tissues. Then, we classified 60 patients with melanoma according to the literature (43) , and the results showed that the expression of miR-194 was correlated with TNM stage, primary tumor ulceration, tumor thickness and age of melanoma (Table II) . It is concluded that miR-194 may have a certain effect on the occurrence and development of melanoma, and then through miRDB tool we found many proteins which can interact with miR-194 (Fig. 2B) . After detailed analysis we concluded that the low expression of GEF-H1 in melanoma tissues may be related to miR-194. Since miR-194 could be combined with 3'-uTR of GEF-H1 (Fig. 2C) . We confirmed our inference by the luciferase reporter assay, which showed that miR-194 can indeed reduce the expression of GEF-H1 at the transcriptional level (Fig. 2D) . Results showed found there was a negative correlation between miR-914 and GEF-H1 in melanoma tissues (Fig. 2E) . In order to further verify the relationship between miR-194 and GEF-H1, we transfected miR-194 mimic or miR-194 inhibitor into A375
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cells. Then, we used real-time PCR and western blotting to detect the expression of GEF-H1 and miR-194 (Fig. 2F-I) .
Results showed that the expression of GEF-H1 was markedly downregulated by miR-194. 
miR-194 inhibits the proliferation of melanoma cells by suppressing GEF-H1 pathway.
Numerous studies have indicated that GEF-H1 promotes cell proliferation by regulating the expression of RhoA, thus, we wanted to investigate whether miR-194 regulates the proliferation of melanoma cells by affecting the GEF-H1/RhoA pathway. MTT assay was used to examine the effect of miR-194 on cell proliferation. The proliferation of A375 and A875 were significantly depressed by transfection with miR-194 mimic (Fig. 3A) . On the contrary, when transfected with miR-194 inhibitor, we found promotion of cell proliferation (Fig. 3B) . As known, p21 is an important downstream protein in GEF-H1/RhoA pathway. Thus, we overexpressed or downregulated miR-194 and then examined the expression of p21 by western blotting and real-time RT-PCR (Fig. 3C-F) . Results showed that miR-194 can inhibit the expression of GEF-H1 and RhoA, but it significantly increased the expression of p21. Thus, the results showed that miR-194 negatively regulates GEF-H1, then inhibiting the proliferation of A375 by inhibiting the GEF-H1/RhoA pathway. pathway. We used Transwell assay (with or without Matrigel) to study whether miR-194 is involved in metastasis of A375 cells (Fig. 4A-D) . Results showed that the invasion and migration of the A375 cells were significantly inhibited when miR-194 was overexpressed, whereas the invasion and migration of A375 cells were promoted when miR-194 expression was decreased. In addition, through western blotting and real-time PCR we found Ecad and vim were significantly downregulated by miR-194 through GEF-H1/RhoA pathway ( Fig. 4E-H) . These experiments confirmed that miR-194 inhibited the metastasis of melanoma cells by inhibiting the GEF-H1/RhoA pathway.
Discussion
GEF-H1 affects the occurrence and development of a tumor by regulating tumor cell migration, promotes the proliferation of tumor cells and inhibits the apoptosis of tumor cells (19) . It has been reported that GEF-H1 is highly expressed in breast and prostate cancer, myeloid cell tumor and metastatic melanoma, but there were few studies concerning the expression of GEF-H1 in melanoma (10, 19, 20) . GEF-H1 promotes the metastasis of breast cancer cells by inducing the rearrangement of cytoskeleton (20) . In prostate cancer cells GEF-H1 participate in the formation of lamellipodia to promote the migration of cells (44) . GEF-H1 plays a role in promoting tumor cell growth and invasion and metastasis by regulating the expression of RhoA, and then affects the downstream pathway (18) . In colorectal, gastric and non-small cell lung cancer, miR-194 was proved to be able to inhibit the occurrence and development of tumor (42, (45) (46) (47) . Studies have shown that overexpression of miR-194 inhibited cell proliferation and metastasis by targeting proteins such as RBX1 and BMI1 (42, 48) . However, we first demonstrated that miR-194 inhibited the growth and metastasis of melanoma by inhibiting the GEF-H1/RhoA pathway.
In the present study, real-time PCR assay showed that the expression of GEF-H1 in the melanoma tissue was ~27.62% higher than that in the adjacent tissues, however, the expression of miR-194 was ~29.97% lower in tumor tissues than the adjacent tissues. Moreover, we found that miR-194 negatively regulates the expression of GEF-H1, and their correlation formula is y = -0.4054 x x + 0.8377 R 2 = 0.5777. Furthermore, we overregulated or downregulated the expression of miR-194 in melanoma cells, then detected the functions of miR-194 in melanoma cells through the MTT and Transwell assays. We found that miR-194 inhibited the proliferation and invasion of melanoma cells by inhibiting the expression of GEF-H1. In addition, western blotting and real-time PCR showed that miR-194 depresses the expression of Ecad and promotes the expression of p21 which are the proteins in GEF-H1/RhoA pathway.
In conclusion, our studies have demonstrated that miR-194 is closely related to the occurrence and development of melanoma. miR-194 inhibited the proliferation and invasion of melanoma cells by negative regulation the expression of GEF-H1. Clinically, miR-194 expression may be associated with melanoma TNM grade as well as the prognosis of melanoma. In summary, our findings suggest that miR-194 may be considered in targeted therapy in melanoma.
